Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study

被引:12
作者
Descombes, Eric [1 ]
Martins, Filipe [1 ]
Hemett, Ould Maouloud [1 ]
Erard, Veronique [2 ]
Chuard, Christian [2 ]
机构
[1] HFR Fribourg Hop Cantonal, Dept Internal Med, Serv Nephrol, Fribourg, Switzerland
[2] HFR Fribourg Hop Cantonal, Dept Internal Med, Infect Dis Serv, Fribourg, Switzerland
关键词
Hemodialysis; Beta-lactam antibiotics; Cefepime; Pharmacokinetics; DIALYSIS PATIENTS; RENAL-FUNCTION; PHARMACOKINETICS; NEUROTOXICITY; IMPAIRMENT; INFECTION; ADHERENCE; OUTCOMES; DISEASE;
D O I
10.1186/s40360-016-0048-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: In hemodialysis patients, post-dialysis treatment with intravenous antibiotics permits even severe infections to be managed on an outpatient basis. Cefepime is a fourth-generation cephalosporin with a broad spectrum of action in monotherapy. We report on the pharmacokinetics of cefepime in post-dialysis therapy. Methods: Since June 2012, twelve infections were treated with post-dialysis cefepime in 9 patients on high-flux hemodialysis. The initial post-dialysis dose of cefepime was approximately 15 mg/kg. The following doses were adapted according to the trough serum levels obtained before the subsequent dialysis in order to be above the EUCAST breakpoints for susceptible organisms and above the MIC90. Residual plasma concentrations were determined before (n = 30) and after (n = 17) dialysis by liquid chromatography-mass spectrometry. Results: Overall, the mean +/- SD dose of cefepime was 920 +/- 270 mg (14.5 +/- 5.1 mg/kg), but it was significantly lower before the 48 h interval (775 +/- 210 mg or 12.7 +/- 4.5 mg/kg) compared to the 72 h interval (1125 +/- 225 mg or 17.2 +/- 4.9 mg/kg) (p < 0.05). The mean trough pre-dialysis concentrations were 10.7 +/- 3.9 mg/l and 11.3 +/- 5.6 mg/l at 48 and 72 h, respectively. These levels always largely exceeded the EUCAST susceptibility breakpoints for all the targeted bacteria (> 1 mg/l) with the exception of Pseudomonas aeruginosa (> 8 mg/l). Cefepime concentrations were higher in anuric patients compared to those with preserved diuresis (15.6 +/- 3.5 vs 9.25 +/- 3.6 mg/l; p < 0.001) and decreased on average by 81 % during dialysis (from 10.5 +/- 3.7 to 1.96 +/- 1.2 mg/l; p < 0.001). The clinical outcome of all patients was good. Conclusions: Outpatient treatment with cefepime administered post-dialysis three-times-weekly was effective and well-tolerated in our patients. According to our data, in patients infected by highly susceptible pathogens a fixed dose of cefepime of 1 g before every 48-h interval and of 1.5 g before every 72-h interval should be recommended, without need of routine monitoring of the cefepime blood levels. In patients having an infection with less susceptibles pathogens as P. aeruginosa, and particularly in those among them exhibiting residual renal function, higher initial doses are necessary (1.5 g before a 48-h interval and 2.0 g before a 72-h interval) with adaption according to the subsequent pre-dialysis trough serum levels.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Significance of mild thrombocytopenia in maintenance hemodialysis patients; a retrospective cohort study
    Toyoda, Yukiko
    Tateno, Kaoru
    Takeda, Yorinobu
    Kobayashi, Yoshio
    PLATELETS, 2022, 33 (05) : 735 - 742
  • [32] Post-hospitalization dialysis facility processes of care and hospital readmissions among hemodialysis patients: a retrospective cohort study
    Plantinga, Laura C.
    Masud, Tahsin
    Lea, Janice P.
    Burkart, John M.
    O'Donnell, Christopher M.
    Jaar, Bernard G.
    BMC NEPHROLOGY, 2018, 19
  • [33] Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study
    Ohta, Shoichiro
    Yasuno, Nobuhiro
    Inomoto, Yuki
    Matsuda, Kaori
    Nakagawa, Yoshihiko
    Sasagawa, Isoji
    Tanaka, Masahiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 7 (01) : 27 - 30
  • [34] Study on Dialysis Session Length and Mortality in Maintenance Hemodialysis Patients: The Q-Cohort Study
    Fujisaki, Kiichiro
    Tanaka, Shigeru
    Taniguchi, Masatomo
    Matsukuma, Yuta
    Masutani, Kosuke
    Hirakata, Hideki
    Kitazono, Takanari
    Tsuruya, Kazuhiko
    NEPHRON, 2018, 139 (04) : 305 - 312
  • [35] Combined Therapy with Peritoneal Dialysis and Hemodialysis: A Multicenter Retrospective Observational Cohort Study in Japan
    Maruyama, Yukio
    Yokoyama, Keitaro
    Nakayama, Masaaki
    Higuchi, Chieko
    Sanaka, Tsutomu
    Tanaka, Yoshihide
    Sakai, Ken
    Mizuiri, Sonoo
    Otsuka, Yasushi
    Kuriyama, Satoru
    Maeba, Teruhiko
    Iwasawa, Hideaki
    Nakao, Toshiyuki
    Hosoya, Tatsuo
    BLOOD PURIFICATION, 2014, 38 (02) : 149 - 153
  • [36] Characteristics and Influencing Factors of Intra-Dialysis Blood Pressure Variability in Hemodialysis Patients: A Retrospective Study
    Xu, Haifan
    Wang, Xiaoshuang
    Feng, Miao
    Chen, Liqun
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17 : 4781 - 4791
  • [37] Serum zinc levels in hemodialysis and peritoneal dialysis patients: A retrospective observational study
    Mahmoudi, Masoud
    Moeinzadeh, Firouzeh
    Atapour, Abdolamir
    Seirafian, Shiva
    Azhir, Zhina
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2024, 29 (01):
  • [38] Comparison of Serum Urea, Salivary Urea, and Creatinine Levels in Pre-Dialysis and Post-Dialysis Patients: A Case-Control Study
    Bhuvaneswari, Vaishnavi Nagarajan
    Alexander, Hariharan
    Shenoy, Mamatha T.
    Sriramulu, D.
    Kanakasekaran, Suganthy
    Kumar, Mohanty Pradipta
    Murugiah, Viveka
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [39] Mortality in hemodialysis patients in Ethiopia: a retrospective follow-up study in three centers
    Desta, Beza Zewdu
    Dadi, Abel Fekadu
    Derseh, Behailu Tariku
    BMC NEPHROLOGY, 2023, 24 (01)
  • [40] Effect of intestinal dialysis using polyethylene glycol on fluid balance and thirst in maintenance hemodialysis patients: A comparative study
    Bhuwania, Puneet
    Veerappan, Ilangovan
    Sethuraman, Ramaswami
    Rajgopal, Ananthasubramaniam
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (02) : 398 - 408